EXPRESSION OF TIM-3 BY IMMUNE CELLS IN MICE WITH AN EXPERIMENTAL MODEL OF THE TUMOR PROCESS

Authors

  • Alesia V. Vialichka Belarusian State Medical University, Research Institute of Experimental and Clinical Medicine , International Sakharov Environmental Institute, Belarusian State University
  • Elizaveta M. Nazaranka Belarusian State Medical University, Research Institute of Experimental and Clinical Medicine
  • Dmitry V. Lutskovich Republican Scientific and Practical Center for Children’s Oncology, Hematology and Immunology
  • Darya B. Nizheharodava Belarusian State Medical University, Research Institute of Experimental and Clinical Medicine

Keywords:

tumor microenvironment, neoplasm, immune cells, experimental model, immune checkpoints, T-cell immunoglobulin and mucin domain-3

Abstract

T-cell immunoglobulin and mucin domain-3 (TIM-3) is an inhibitory immune checkpoint that is expressed on immune and tumor cells. However, to date, the dual role of TIM-3 has been shown: on the one hand, the receptor acts as a negative regulator of antitumor immunity and is associated with a lower survival rate in cancer patients, and on the other hand, it may indicate a positive prognosis for certain types of cancer.

The study was conducted on A/J mice with an experimental neuroblastoma model. The cellular composition of the secondary organs of the immune system and TIL (tumor-infiltrating lymphocytes), as well as the level of TIM-3 expression, were determined using flow cytometry and monoclonal antibodies. Statistical processing is performed in Statistica 8.0. 

The secondary lymphoid organs of the immune system (lymph nodes and spleen) were characterized by a predominant (more than 90%) content of lymphocytes, while the remaining cells were identified as granulocytes and monocytes/macrophages in all the studied groups. At the same time, the content of tumor-associated macrophages (TAM) increased statistically significantly in the TIL population of mice in the experimental group. In mice with an experimental neuroblastoma model, a decrease in CD3+ T-lymphocytes in the lymph nodes and spleen was found relative to the comparison group (p=0.01) in combination with an increase in CD3+CD4-CD8-T-cells in the lymph nodes (p=0.01). In the experimental group, there was a statistically significant increase in TIM-3 on CD3+T-lymphocytes, mainly on CD3+CD8+T-cells. An inverse relationship was found between the level of TIM-3 expression on CD3+CD8+T-lymphocytes and the amount of TAM (R=-0.70; p=0.02) in lymph nodes, as well as the correlation of TIM-3 expression on CD3+ T-lymphocytes of the spleen and TAM content in mice with neuroblastoma (R=0.90; p=0.001), which may be a potential mechanism of pathological immune tolerance in the formation of the oncological process.

Author Biographies

  • Alesia V. Vialichka, Belarusian State Medical University, Research Institute of Experimental and Clinical Medicine, International Sakharov Environmental Institute, Belarusian State University

    graduate student at the department of immunologya; junior researcher at the laboratory of immunology and biomedical technologyb

  • Elizaveta M. Nazaranka, Belarusian State Medical University, Research Institute of Experimental and Clinical Medicine

    junior researcher at the laboratory of immunology and biomedical technology

  • Dmitry V. Lutskovich, Republican Scientific and Practical Center for Children’s Oncology, Hematology and Immunology

    researcher at the laboratory of genetic biotechnologies

  • Darya B. Nizheharodava, Belarusian State Medical University, Research Institute of Experimental and Clinical Medicine

    PhD (biology), docent; head of the laboratory of immunology and biomedical technologies

References

  1. Hecka J, Parka AS, Qiu J. An exploratory study of ambient air toxics exposure in pregnancy and the risk of neuroblastoma in offspring. Environmental Research. 2013;127:1–6. DOI: 10.1016/j.envres.2013.09.002.
  2. Ducimetiee L, Vermeer M, Tugues S. The Interplay Between Innate Lymphoid Cells and the Tumor Microenvironment. Frontiers in Immunology. 2019;10:1–11. DOI: 10.3389/fimmu.2019.02895.
  3. Haas L, Obenauf AC. Allies or Enemies-The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment. Frontiers in Immunology. 2019;10:1–11. DOI: 10.3389/fimmu.2019.02746.
  4. Habanjar O, Bingula R, Decombat C. Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment. International Journal of Molecular Sciences. 2023;24(4):1–40. DOI: 10.3390/ijms24044002.
  5. Talvard-Balland N, Braun L, Dixon K. Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice. The Journal of Clinical Investigation. 2024;134(16):1–17. DOI: 10.1172/JCI177460.
  6. Kushekhar K, Chellappa S, Aandahl E. Role of Lymphocytes in Cancer Immunity and Immune Evasion Mechanisms. Biomarkers of the Tumor Microenvironment. 2022;37:159–182. DOI: 10.1007/978-3-030-98950-7_10
  7. Habanjar O, Bingula R, Decombat C. Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment. International Journal of Molecular Sciences. 2023;24(4):1–40. DOI: 10.3390/ijms24044002.
  8. Shaul ME, Fridlender ZG. Cancer-related circulating and tumor-associated neutrophils – subtypes, sources and function. The Microbiome in Health and Disease. 2018;285:4316–4342. DOI: 10.1111/febs.14524.
  9. Osipov A, Saung MT, Zheng L. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. Journal for Immunotherapy of Cancer. 2019;7(1):1–12. DOI: 10.1186/s40425-019-0667-0.
  10. SenGupta S, Hein LE, Parent CA. The Recruitment of Neutrophils to the Tumor Microenvironment Is Regulated by Multiple Mediators. Frontiers in Immunology. 2021;12:1–10. DOI: 10.3389/fimmu.2021.734188.
  11. Jakubowska K, Koda M, Grudzińska M. Monocyte-to-lymphocyte ratio as a prognostic factor in peripheral whole blood samples of colorectal cancer patients. World Journal of Gastroenterology. 2020;26(31):4639–4655. DOI: 10.3748/wjg.v26.i31.4639.
  12. Jeong J, Suh Y, Jung K. Context Drives Diversification of Monocytes and Neutrophils in Orchestrating the Tumor Microenvironment. Frontiers in Immunology. 2019;10:1–20. DOI: 10.3389/fimmu.2019.01817.
  13. Messex JK, Byrd CJ, Liou GY. Signaling of Macrophages that Contours the Tumor Microenvironment for Promoting Cancer Development. Cells. 2020;9(4):1–15. DOI: 10.3390/cells9040919.
  14. Laumont CM, Nelson BH. B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell. 2023;41(3):466–489. DOI: 10.1016/j.ccell.2023.02.017.
  15. Zheng Z, Wieder T, Mauerer B. T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment. International Journal of Molecular Sciences. 2023;24(14):1–35. DOI: 10.3390/ijms241411673.
  16. Li C, Jiang P, Wei S. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Molecular Cancer. 2020;19(1):1–23. DOI: 10.1186/s12943-020-01234-1.
  17. Kraja F, Jurisic VB, Hromić-Jahjefendić H. Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling. Frontiers Immunology. 2025;16: 1–21. DOI: 10.3389/fimmu.2025.1601773.
  18. Hinshaw DC, Shevde LA. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Research. 2019;79(18):4557–4566. DOI: 10.1158/0008-5472.CAN-18-3962.
  19. Wang H, Yung MH, Ngan HS. The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression. International Journal of Molecular Sciences. 2021;22(12):1–19. DOI: 10.3390/ijms22126560.
  20. Haas L, Obenauf AC. Allies or Enemies-The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment. Frontiers in Immunology. 2019;10:1–11. DOI: 10.3389/fimmu.2019.02746.
  21. Codrici E, Popescu ID, Tanase C. Friends with Benefits: Chemokines, Glioblastoma-Associated Microglia/Macrophages, and Tumor Microenvironment. International Journal of Molecular Sciences. 2022;23(5):1–36. DOI: 10.3390/ijms23052509.
  22. Hagen M, Pangrazzi L, Rocamora-Reverte L. Legend or Truth: Mature CD4+CD8+ Double-Positive T Cells in the Periphery in Health and Disease. Biomedicines. 2023;11:1–11. DOI: 10.3390/biomedicines11102702.
  23. Wu Z, Zheng Y, Sheng J. CD3+CD4-CD8- Double-Negative T Cells in Inflammation, Immune Disorders and Cancer. Frontiers in Immunology. 2022;13:1–14. DOI: 10.3389/fimmu.2022.816005.
  24. Neophytou CM, Panagi M, Stylianopoulos T. The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities. Cancers. 2021;13:1–22. DOI: 10.3390/cancers13092053.
  25. Arneth B. Tumor Microenvironment. Medicina. 2019;56(1):1–15. DOI: 10.3390/medicina56010015.
  26. Itahashi K, Irie T, Nishikawa H. Regulatory T-cell development in the tumor microenvironment. European Journal of Immunology. 2022;52(8):1216–1227. DOI: 10.1002/eji.202149358.
  27. Pagliano O, Morrison R, Chauvin J. Tim-3 mediates T cell trogocytosis to limit antitumor immunity. The Journal of Clinical Investigation. 2022;132(9);1–16. DOI: 10.1172/JCI152864.
  28. Qin S, Dong B, Yi M. Prognostic Values of TIM-3 Expression in Patients with Solid Tumors: A Meta-Analysis and Database Evaluation. Frontiers in Oncology. 2020;10(1288):1–13. DOI: 10.3389/fonc.2020.01288.

Downloads

Published

2026-01-12

Issue

No. 4 (2025): ЖУРНАЛ БЕЛОРУССКОГО ГОСУДАРСТВЕННОГО УНИВЕРСИТЕТА ЭКОЛОГИЯ

Section

Medical Ecology

How to Cite

[1]
Vialichka, A. et al. 2026. EXPRESSION OF TIM-3 BY IMMUNE CELLS IN MICE WITH AN EXPERIMENTAL MODEL OF THE TUMOR PROCESS. Journal of the Belarusian State University. Ecology. 4 (Jan. 2026), 42–51.